PHVS Healthcare

Pharvaris N.V.

$34.78+3.73%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Switzerland
Market cap: 2.4B USD
Enterprise value: 2.1B USD
Full-time employees: 148

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Pharvaris looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to December 2025.
Pharvaris reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.
Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.
Pharvaris has among the least debt in its peer group relative to shareholders' equity.

StockQuotient Score

—

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-8.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025 · EUR→USD at the current rateNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-9.9%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 months · EUR→USD convertedNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-6.8%

SEC filings (IFRS mapped) · 12 months to Dec 2025 · EUR→USD at the current rate · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield13.4%

SEC filings (IFRS mapped) · latest balance sheet · EUR→USD at the current rateReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio11.94×

Yahoo Finance fallback · SEC figure unavailable or out of dateReported value33% base weight · Z-score 6.75Sector median: 2.5860 · MAD: 1.3850

Debt / equity<0.01×

Yahoo Finance fallback · no standard SEC debt tagOutlier capped at sector 5th/95th percentile33% base weight · Z-score 1.07Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Pharvaris

Is Pharvaris getting weaker?: Its latest SEC filing (Apr 2, 2026) showed no major changes.
How is Pharvaris valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -8.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.7% vs peers 1.5% (weaker than 100% of peers).
Is Pharvaris growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Pharvaris?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Pharvaris?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity <0.01× vs a peer median of 0.22× (stronger than 95% of peers).Debt / equity <0.01× vs peers 0.22× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Dec 31, 2025 · filed Apr 2, 2026 · compared with the quarter ended Jun 30, 2025

No major changes

	Previous quarter	Latest quarter	Change
Net income (12 months)	−168.3M EUR	−175.7M EUR	+4.4%
Free cash flow (12 months)	−137.3M EUR	−137.2M EUR	−0.0%
Cash	199.6M EUR	291.7M EUR	+46.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year · amounts in EUR, as reported

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-20.1%	-45.5%	-25.3%	-46.1%	-58.3%	▼ 12 pts
Return on equity (ROE)	-20.8%	-51.1%	-26.3%	-50.1%	-64.8%	▼ 15 pts
Interest coverage	-159.47×	-4697.51×	—	—	—	—

PHVS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Pharvaris looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to December 2025.

Pharvaris reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.

Pharvaris has among the least debt in its peer group relative to shareholders' equity.

Questions investors ask about Pharvaris

Is Pharvaris getting weaker?

Its latest SEC filing (Apr 2, 2026) showed no major changes.

How is Pharvaris valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -8.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.7% vs peers 1.5% (weaker than 100% of peers).

Is Pharvaris growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Pharvaris?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Pharvaris?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity <0.01× vs a peer median of 0.22× (stronger than 95% of peers).Debt / equity <0.01× vs peers 0.22× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−168.3M EUR

−175.7M EUR

+4.4%

Free cash flow (12 months)

−137.3M EUR

−137.2M EUR

−0.0%

Cash

199.6M EUR

291.7M EUR

+46.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-20.1%

-45.5%

-25.3%

-46.1%

-58.3%

▼ 12 pts

Return on equity (ROE)

-20.8%

-51.1%

-26.3%

-50.1%

-64.8%

▼ 15 pts

Interest coverage

-159.47×

-4697.51×

—